(R)-3-氨基-1-苄基哌啶 | 168466-84-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: (R)-3-氨基-1-苄基哌啶
• 中文别名: (R)-1-苄基-3-氨基哌啶
• 英文名称: (R)-3-amino-1-benzylpiperidine
• 英文别名: (R)-1-benzylpiperidin-3-amine；(R)-1-benzyl-3-aminopiperidine；(3R)-1-benzylpiperidin-3-amine
• CAS: 168466-84-0
• 化学式: C₁₂H₁₈N₂
• 分子量: 190.288
• InChiKey: HARWNWOLWMTQCC-GFCCVEGCSA-N

物化性质

• 沸点：
  281.2±33.0 °C(Predicted)
• 密度：
  1.037±0.06 g/cm3(Predicted)
• 闪点：
  113℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933399090
• WGK Germany：
  3
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P301+P310
• 危险品运输编号：
  2811
• 危险性描述：
  H301
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
(R)-1-Benzylpiperidin-3-amine
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
(R)-1-Benzylpiperidin-3-amine
Ingredient name:
CAS number: 168466-84-0

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C12H18N2
Molecular weight: 190.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (R)-3-氨基-1-苄基哌啶 在 lithium aluminium tetrahydride 、 potassium carbonate 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 22.17h， 生成 (R)-N-(1-benzylpiperidine-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidine-4-amine
  参考文献：
  名称：

  Design, synthesis and evaluation of (R)-3-(7-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-5-azaspiro[2.4]heptan-5-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor

  摘要：

  我们发现了一种新的选择性JAK1抑制剂，其选择性指数为48，并确定了其在CIA和AIA模型中的有效性。

  DOI：

  10.1039/c7md00568g
• 作为产物：
  描述：

  (R)-1-benzylpiperidine-3-carboxylic azide 在 硫酸 作用下， 以 水 为溶剂， 反应 1.0h， 以35 g的产率得到(R)-3-氨基-1-苄基哌啶
  参考文献：
  名称：

  一种手性3-氨基哌啶及其衍生物的合成方法

  摘要：

  本发明涉及手性3‑氨基哌啶及其衍生物的合成方法。本发明通过R(或S)‑哌啶‑3‑甲酸乙酯‑L(或D)‑酒石酸盐经苄基保护后进行肼解反应，然后经叠氮化和Curtius重排得R或S‑1‑苄基‑3‑氨基哌啶。R或S‑1‑苄基‑3‑氨基哌啶经过脱苄基可得到R或S‑3‑氨基哌啶，R或S‑1‑苄基‑3‑氨基哌啶通过3‑叔丁氧羰基保护，再脱苄基可得到R或S‑(3‑叔丁氧羰基氨基)哌啶，R或S‑(3‑叔丁氧羰基氨基)哌啶在酸性条件下水解脱保护可得到R或S‑3‑氨基哌啶相应的盐。该合成方法提供一种低成本，易工业化且具有高光学纯度的手性3‑氨基哌啶及其衍生物的方法。

  公开号：

  CN110078657A
• 作为试剂：
  描述：

  、 sodium hydroxide 、 3-氨基-1-苄基哌啶 在 甲苯 、 (R)-3-氨基-1-苄基哌啶 作用下， 以Thus, 17.7 g of (R)—N-benzyl-3-aminopiperidine were obtained in the form of colorless oil的产率得到(R)-3-氨基-1-苄基哌啶
  参考文献：
  名称：

  Method for producing optically-active amine compound, recombinant vector, and transformant containing the vector

  摘要：

  本发明涉及一种制备光学活性胺化合物的方法。该方法的特点是在相同的反应体系中使用具有特定特性的转氨酶(A)，α-酮酸还原酶(B)和酶(C)，将酮化合物转化为相应的光学活性胺化合物，其中含有与氨基团键合的碳原子作为不对称点。本发明还涉及一种用于该方法的重组载体。本发明使得能够高效地生产光学活性胺化合物。

  公开号：

  US08168412B2

文献信息

• AZACYCLYLISOQUINOLINONE AND ISOINDOLINONE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS
  申请人：Zhou Dahui

  公开号：US20090069370A1

  公开（公告）日：2009-03-12

  The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor.

  本发明提供了一种公式I的化合物，以及该化合物用于治疗与组胺-3受体相关或受其影响的中枢神经系统疾病。
• [EN] SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS<br/>[FR] PYRROLOPYRIDINES SUBSTITUÉES EN TANT QU'INHIBITEURS DE JAK
  申请人：ACLARIS THERAPEUTICS INC

  公开号：WO2020223728A1

  公开（公告）日：2020-11-05

  The present invention relates to new pyrrolopyridine compounds having the structures of Formula (I)-(IV), wherein the R groups, A, B, C, D and n are as defined in the detailed description, and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.

  本发明涉及具有化学式（I）-（IV）结构的新吡咯吡啶化合物，其中R基团，A、B、C、D和n的定义如详细说明中所述，以及这些化合物及其应用作为治疗疾病的药物。还提供了用于治疗疾病如瘙痒症、脱发、雄激素性脱发、斑秃、白癜风和牛皮癣的方法，用于抑制人类或动物主体中JAK激酶活性。
• 6-(4-Hydroxy-phenyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
  申请人：SANOFI

  公开号：US20130150340A1

  公开（公告）日：2013-06-13

  The present invention relates to 1H-pyrazolo[3,4-b]pyridine compounds of the formula I, in which R 1 , R 2 , R 3 and R 4 are defined as indicated below. The compounds of the formula I are kinase inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula I, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I的1H-吡唑并[3,4-b]吡啶化合物，其中R1、R2、R3和R4如下所示。式I的化合物是激酶抑制剂，对于治疗与糖尿病及糖尿病并发症相关的疾病，如糖尿病肾病、糖尿病神经病变和糖尿病视网膜病变等，具有用处。此外，本发明还涉及将式I的化合物用作药物中的活性成分，以及包含它们的药物组合物。
• Discovery of a PCAF Bromodomain Chemical Probe
  作者：Moses Moustakim、Peter G. K. Clark、Laura Trulli、Angel L. Fuentes de Arriba、Matthias T. Ehebauer、Apirat Chaikuad、Emma J. Murphy、Jacqui Mendez‐Johnson、Danette Daniels、Chun‐Feng D. Hou、Yu‐Hui Lin、John R. Walker、Raymond Hui、Hongbing Yang、Lucy Dorrell、Catherine M. Rogers、Octovia P. Monteiro、Oleg Fedorov、Kilian V. M. Huber、Stefan Knapp、Jag Heer、Darren J. Dixon、Paul E. Brennan

  DOI：10.1002/anie.201610816

  日期：2017.1.16

  bromodomain‐containing lysine acetyl transferases are members of subfamily I of the bromodomain phylogenetic tree. Iterative cycles of rational inhibitor design and biophysical characterization led to the discovery of the triazolopthalazine‐based L‐45 (dubbed L‐Moses) as the first potent, selective, and cell‐active PCAF bromodomain (Brd) inhibitor. Synthesis from readily available (1R,2S)‐(−)‐norephedrine furnished

  p300 / CBP相关因子（PCAF）和相关的GCN5含溴结构域的赖氨酸乙酰基转移酶是溴结构域系统发育树的亚家族I的成员。合理的抑制剂设计和生物物理特征的反复循环导致发现了基于三唑并噻嗪的L-45（称为L-Moses）作为第一种有效的，选择性的和具有细胞活性的PCAF溴结构域（Brd）抑制剂。由易于获得的（1R，2S）-（-）-去氧麻黄碱合成的对映纯形式的L-45。L-45显示出扰乱使用nanoBRET测定细胞PCAF-BRD组蛋白H3.3相互作用，和的共晶体结构L-45与来自恶性疟原虫的同源Brd PfGCN5的组合合理化了对PCAF和GCN5溴结构域的高选择性。化合物L-45在外周血单核细胞（PBMC）中没有可观察到的细胞毒性，在人和小鼠肝微粒体中没有良好的细胞渗透性和代谢稳定性，支持其在体内使用的潜力。
• Rh(I)/Bisoxazolinephosphine-Catalyzed Regio- and Enantioselective Allylic Substitutions
  作者：Wen-Bin Xu、Samir Ghorai、Wenyu Huang、Changkun Li

  DOI：10.1021/acscatal.0c00712

  日期：2020.4.17

  Rhodium(I)/bisoxazolinephosphine combination has been developed as a general catalyst to achieve the dynamic kinetic asymmetric allylation of a variety of nitrogen, carbon, oxygen, and sulfur pronucleophiles from branched racemic allylic carbonates. Exclusive branch-selectivity and up to 99% enantiomeric excess could be obtained under neutral conditions. Linear allylic substrates (both Z and E) could

  铑（I）/双恶唑啉膦组合已被开发为通用催化剂，可实现支链消旋烯丙基碳酸酯中各种氮，碳，氧和硫亲核试剂的动态动力学不对称烯丙基化。在中性条件下可以获得独家的分支选择性和高达99％的对映体过量。线性烯丙基底物（Z和E）也可以转化为具有出色的区域选择性和对映选择性的相同手性支链产物。分离并表征了手性π-烯丙基-Rh（III）/ NPN中间体，以了解高选择性的起源。